Search company, investor...



Series B | Alive

Total Raised


Last Raised

$32M | 5 yrs ago

About Eddingpharm

Eddingpharm, headquartered in Shanghai, is a leading specialty pharmaceuticals company in the fast growing China market. The Company is focused on medical nutrition and oncology therapeutic areas and became a leading commercialization platform for pharmaceutical products in China. To date, Eddingpharm has been granted exclusive market rights of more than 16 products and achieved outstanding performance on marketed products through its 23 district offices reaching over 1000 hospitals in China. Eddingpharm has become the partner of choice for multiple global pharmaceutical companies and continues to expand further alliance opportunities with international partners. Additionally, the Company is currently building R&D and manufacturing capabilities through strategic alliances, enabling it to develop customized pipeline best fitted for Chinese healthcare market.

Headquarters Location


Missing: Eddingpharm's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Eddingpharm's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Eddingpharm

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Eddingpharm is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Eddingpharm News

EOC Pharma Raises $71 Million in C Round for China Development of InLicensed Oncology Drugs

Dec 3, 2019

02:02 EST 3 Dec 2019 | ChinaBio Today EOC Pharma, the oncology development arm of China in- licensing company Eddingpharm, raised $71 million in a Series C round led by Tigermed, TF Capital and Yingke PE. Headquartered in Taizhou, EOC manufactures and commercializes oncology products for China use that require mid to late stage clinical development for registration. It currently has a pipeline of six novel products from global biopharmas, including its most recent in-licensing, a Shionogi HER2/EGFR inhibitor intended to treat brain metastasis in advanced metastatic breast cancer patients. Two years ago, EOC completed a $32 million B financing.

Eddingpharm Frequently Asked Questions (FAQ)

  • What is Eddingpharm's latest funding round?

    Eddingpharm's latest funding round is Series B.

  • How much did Eddingpharm raise?

    Eddingpharm raised a total of $56M.

  • Who are the investors of Eddingpharm?

    Investors of Eddingpharm include Sequoia Capital China, Taikang Life Insurance, H&Q Asia Pacific, OrbiMed Advisors, Domain Associates and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.